Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering is well-positioned in the biopharmaceutical industry due to its unique Disease Cancelling Technology platform that has shown strong early activity in the 1L setting for oncologic and neurologic diseases. While the company faces financing risks and potential dilution, its current cash position of $198.6 million provides a strong base for continued growth and success. Additionally, Immuneering's competitive positioning with atebimetinib, highlighted by its superior tolerability, durability of response, and preservation of body mass, could drive upward momentum for the company's stock and positively impact its future financials.

Bears say

Immuneering is currently a clinical stage company that is facing high levels of competition in the biotechnology sector. Despite its focus on developing novel treatments for debilitating diseases and its proprietary computational Disease Cancelling Technology platform, there are numerous other players also pursuing the development of RAS inhibitors, which could limit Immuneering's market share and potential revenue. Additionally, there is a risk that Immuneering's products may not obtain regulatory approval, which could lead to downward revisions in financial projections and price targets. It is therefore important for investors to closely monitor Immuneering's clinical progress and regulatory status before making any investment decisions.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.